COMMUNIQUÉS West-GlobeNewswire

Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
24/09/2026
Collaboration leverages Atavistik Bio’s proprietary AMPS TM platform to identify and advance novel allosteric small molecules against multiple targets for cardiometabolic diseases Atavistik Bio to receive $70 million [...]
What CX Leaders Should Understand About Customer Support Outsourcing
24/09/2026
Transcom supports more than 300 clients globally, including disruptive e-commerce players and category-redefining fintechs, across 29 countries. Transcom's autopilot conversational AI bots resolve high-volume contacts [...]
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
24/09/2026
TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting [...]
Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic
24/09/2026
Dr. Nora Dimon, VP of Clinical Development, to present preclinical findings on the Company’s lead retinal program, CoTx-101, including non-human primate data Rodolphe Clerval, CEO, to deliver a corporate presentation at [...]
Kraig Biocraft Laboratories Reaches Major Scientific Milestone with Completion of Functional and Living Atlas Gene Library
24/09/2026
ANN ARBOR, Mich., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a major [...]
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
24/09/2026
BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision [...]
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
24/09/2026
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel ARLINGTON, Mass., Sept. 24, 2026 ( [...]
Immuneering to Present at the ESMO Congress 2026
24/09/2026
- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients - NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation ( [...]
Sofwave Receives NMPA Approval in Mainland China
24/09/2026
NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a [...]
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
24/09/2026
Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to [...]
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
24/09/2026
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3- [...]
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
24/09/2026
Fort Lee, NJ, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
24/09/2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function SOUTH SAN FRANCISCO and [...]
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
24/09/2026
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 [...]
Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma
24/09/2026
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics , a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 [...]
Precision Neuroscience Closes Oversubscribed $250M Series D Led by Pershing Square Inc., the Ackman Oxman Institute, and a Leading Life Sciences Investment Fund
24/09/2026
The round brings Precision's total capital raised to $430 million and follows more than 100 patient procedures across 18 major medical institutions NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience [...]
Biolinq Shine™ Receives FDA 510(k) Clearance for Over-the-Counter Use
24/09/2026
First needle-free wearable that tracks glucose, activity and sleep in a single device SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biolinq Incorporated , a pioneering developer of precision multi-analyte biosensors to [...]
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
24/09/2026
Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. ( [...]
Cronos Hosts 2026 Investor Day
24/09/2026
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos [...]

Pages